Inventor · disambiguated record
John Michael Ketcham
Also filed as: KETCHAM JOHN MICHAEL
22 granted patents·19 pending applications·65 citations·filing 2017–2025
93Inventor score
Top patents by PatentIndex Score
41 records- 0196US11453683B1KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·13 cites·84 claims
- 0296US11091495B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Aug 17, 2021·4 cites·26 claims
- 0394US10683280B2Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2019·Granted Jun 16, 2020·8 cites·22 claims
- 0493US11384064B2Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2020·Granted Jul 12, 2022·3 cites·28 claims
- 0592US11964989B2KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·2 cites·19 claims
- 0692US11220509B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Jan 11, 2022·2 cites·27 claims
- 0792US11192879B2Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2020·Granted Dec 7, 2021·3 cites·28 claims
- 0891US10647715B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted May 12, 2020·10 cites·9 claims
- 0991US10246462B2Chemokine receptor modulators and uses thereofFLX BIO INC·Filed 2017·Granted Apr 2, 2019·10 cites·77 claims
- 1090US10179787B2Chemokine receptor modulators and uses thereofFLX BIO INC·Filed 2017·Granted Jan 15, 2019·5 cites·38 claims
- 1187US10604526B2Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2018·Granted Mar 31, 2020·2 cites·25 claims
- 1284US11479551B2MTA-cooperative PRMT5 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Oct 25, 2022·1 cites·30 claims
- 1383US2025059167A1Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1482US2025282787A1SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORSMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1581US2024199620A1Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1680US12371435B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Jul 29, 2025·0 cites·20 claims
- 1777US12304915B2SOS1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted May 20, 2025·0 cites·81 claims
- 1877US12098139B2Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2022·Granted Sep 24, 2024·0 cites·24 claims
- 1977US2024309020A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2075US2025270220A1Sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2173US10722514B2Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereofFLX BIO INC·Filed 2018·Granted Jul 28, 2020·2 cites·33 claims
- 2272US2023054883A1MTA-Cooperative PRMT5 InhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2368US11492351B2MTA-cooperative PRMT5 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Nov 8, 2022·0 cites·27 claims
- 2468US2020262837A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2567US11702418B2SOS1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Jul 18, 2023·0 cites·72 claims
- 2667US2024391882A1Substituted QuinoxalinesMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2766US11485738B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted Nov 1, 2022·0 cites·18 claims
- 2866US2020239480A1Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2966US2025382290A1Salts of sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3065US2025032497A1Combination therapiesMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3161US12280055B2Combination therapiesMIRATI THERAPEUTICS INC·Filed 2022·Granted Apr 22, 2025·0 cites·34 claims
- 3260US12252493B2Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancerMIRATI THERAPEUTICS INC·Filed 2020·Granted Mar 18, 2025·0 cites·27 claims
- 3360US2025179082A1Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancerMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3459US2025059182A1Sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3559US2020308170A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3657US2024208912A1MTA-Cooperative PRMT5 InhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3755US2023312482A1Sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3854US2023101312A1Sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3953US2023279025A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4050US12421228B2Naphthyridine derivatives as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Sep 23, 2025·0 cites·29 claims
- 4148US2021317134A1Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John Michael Ketcham files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →